Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tempus AI, Inc. Class A Common Stock (TEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: TEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $66.7
1 Year Target Price $66.7
| 4 | Strong Buy |
| 2 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.13% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 9.85B USD | Price to earnings Ratio - | 1Y Target Price 66.7 |
Price to earnings Ratio - | 1Y Target Price 66.7 | ||
Volume (30-day avg) 12 | Beta - | 52 Weeks Range 31.36 - 91.45 | Updated Date 07/12/2025 |
52 Weeks Range 31.36 - 91.45 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -88.27% | Operating Margin (TTM) -26.94% |
Management Effectiveness
Return on Assets (TTM) -43.89% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10485817015 | Price to Sales(TTM) 12.26 |
Enterprise Value 10485817015 | Price to Sales(TTM) 12.26 | ||
Enterprise Value to Revenue 13.05 | Enterprise Value to EBITDA - | Shares Outstanding 168072000 | Shares Floating 100942351 |
Shares Outstanding 168072000 | Shares Floating 100942351 | ||
Percent Insiders 43.27 | Percent Institutions 38.02 |
Upturn AI SWOT
Tempus AI, Inc. Class A Common Stock
Company Overview
History and Background
Tempus AI is a technology company focused on precision medicine through the collection and analysis of molecular and clinical data. Founded in 2015, it has rapidly grown by partnering with healthcare providers to build a comprehensive data and analytics platform for precision medicine.
Core Business Areas
- Data & Insights: Offers comprehensive clinical and molecular data insights, including genomic sequencing and data analytics services, to empower healthcare providers in making personalized treatment decisions.
- Therapeutics: Developing therapeutics using the data and insights generated from its platform, with a focus on oncology.
- Clinical Trials: Facilitating clinical trials by connecting patients with appropriate studies based on their unique molecular profiles.
Leadership and Structure
Eric Lefkofsky is the CEO. The company is structured with departments focusing on data science, genomics, software engineering, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- xT (Genomic Sequencing Test): A comprehensive genomic sequencing test used to identify cancer-driving mutations and inform treatment decisions. Market share is growing but faces competition from Foundation Medicine and Guardant Health. Exact revenue not publicly available yet. Competitors include Foundation Medicine (FMI), Guardant Health (GH).
- TIME (Tempus AI-Enabled Molecular Intelligence): An integrated platform providing access to patient data, molecular profiles, and clinical trial information. Competitors include Flatiron Health (acquired by Roche), and various hospital systems' internal data analytics platforms.
- Tempus Labs: A suite of products that allows to order test, access results, and manage the genomic and clinical information. Competitors include Natera (NTRA), NeoGenomics (NEO)
Market Dynamics
Industry Overview
The precision medicine market is growing rapidly, driven by advances in genomics, data analytics, and personalized healthcare. The industry is characterized by increasing partnerships between technology companies, pharmaceutical companies, and healthcare providers.
Positioning
Tempus AI positions itself as a leading provider of data-driven precision medicine solutions, leveraging its comprehensive data platform and AI-powered analytics to improve patient outcomes.
Total Addressable Market (TAM)
The global precision medicine market is projected to reach hundreds of billions of dollars in the coming years. Tempus AI is positioned to capture a significant portion of this market by providing end-to-end solutions that address the needs of healthcare providers, pharmaceutical companies, and patients. TAM is estimated to be over $200B by 2030, where Tempus is expected to capture a significant percentage.
Upturn SWOT Analysis
Strengths
- Comprehensive data platform
- AI-powered analytics capabilities
- Strong partnerships with healthcare providers
- Focus on precision medicine in oncology
- Experienced leadership team
Weaknesses
- Reliance on data acquisition and partnerships
- Relatively high cash burn
- Dependent on technological advancement to maintain competitive edge
- Profitability concerns
- Limited product diversification outside oncology
Opportunities
- Expansion into new therapeutic areas
- Development of novel diagnostics and therapeutics
- Increased adoption of precision medicine
- Strategic acquisitions and partnerships
- International expansion
Threats
- Competition from established players
- Regulatory hurdles
- Data privacy and security concerns
- Reimbursement challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- Foundation Medicine (FMI)
- Guardant Health (GH)
- Natera (NTRA)
- NeoGenomics (NEO)
Competitive Landscape
Tempus AI differentiates itself through its comprehensive data platform and AI-powered analytics. However, it faces strong competition from established players with significant market share and resources.
Major Acquisitions
Acquired Company Name
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Explain the strategic reasons behind the acquisition.
Growth Trajectory and Initiatives
Historical Growth: Prior to the IPO, growth was fueled by venture capital and strategic partnerships. Post-IPO, growth is expected to accelerate through increased adoption of its products and services.
Future Projections: Analysts project significant revenue growth for Tempus AI, driven by increasing demand for precision medicine solutions.
Recent Initiatives: Tempus AI has recently focused on expanding its data platform, developing new AI-powered analytics tools, and forging strategic partnerships with pharmaceutical companies. Also they launched IPO May 2024
Summary
Tempus AI is a company operating in the rapidly growing precision medicine space. It possesses a strong data platform and AI capabilities, and is poised for growth. However, it also faces challenges including stiff competition, regulatory hurdles and need for sustainable profitability. The company's success will depend on expanding its market share, continued innovation and effective commercialization of its offerings.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market data is subject to change. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tempus AI, Inc. Class A Common Stock
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2024-06-14 | Co-Founder, CEO, President & Chairman Mr. Eric P. Lefkofsky J.D. | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2400 | Website https://www.tempus.com |
Full time employees 2400 | Website https://www.tempus.com | ||
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.